EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
Federal contract awards won by EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (UEI CNPVCR8DK7M8), 2010–2023 — public record from USAspending.
Showing awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
7
awards
1
expiring in 12 months
2
agencies
Category award history
2 category awards to a new vendor (same agency and NAICS code, not this contract's own history) — latest: MAYVIN, INC. took Department of Defense 541715 work from EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (Nov 19, 2026).
Agencies buying from EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
What EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. has provided
541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (3)325414 — BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (1)541712 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT BIOTECHNOLOGY) (1)541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) (1)541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) (1)
Awards
MEDICAL COUNTERMEASURES (MCM) THAT CAN BE DEPLOYED IN THE EVENT OF A FILOVIRUS OUTBREAK ARE A CRUCIAL COMPONENT TO THE UNITED STATES GOVERNMENT?S (USG?S) OUTBREAK RESPONSE PLAN. BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) IS SEEKIN
Department of Health and Human Services · $237,127,358 · Jul 31, 2023
CREATION OF AN FDA APPROVED ANALGESIC KETAMINE DRUG WITH AUTO INJECTOR DELIVERY SYSTEM.
Department of Defense · $26,877,810 · Sep 26, 2019
ACAM2000, SMALLPOX (VACCINIA) VACCINE, LIVE (ACAM)
Department of Health and Human Services · $857,637,641 · Aug 30, 2019
IGF::OT::IGF - ADVANCING STABILIZED ISOAMYL NITRITE FOR INTRANASAL TREATMENT OF CYANIDE EXPOSURE
Department of Health and Human Services · $32,952,759 · Sep 15, 2017
IGF::OT::IGF
Department of Health and Human Services · $1,409,725,727 · Sep 30, 2016
IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS
Department of Health and Human Services · $29,701,453 · Aug 28, 2014
TAS::75 0140::TAS ADVANCED DEVELOPMENT OF RECOMBINANT PROTECTIVE ANTIGENT (RPA) ANTHRAX VACCINE CAN 1990087
Department of Health and Human Services · $92,988,270 · Sep 17, 2010